Primeros casos autóctonos de hepatitis E en Uruguay

Con el objetivo de describir los primeros casos autóctonos de Hepatitis E se realizó un estudio descriptivo. La población, 9 enfermos, se identificó en el periodo noviembre 2009 a julio 2010. Se seleccionaron por IgG e IgM específicas para VHE y se realizó búsqueda de ARN viral en suero por RT-PCR. Presentaron una media de 51 años, 8 del sexo masculino, educación terciaria, nivel socioeconómico medio alto, atención en el sector privado y residencia urbana. La clínica fue similar a Hepatitis A, con transaminasas elevadas por encima de 1500 (mU/ml), la glutamicopiruvica con valores máximos de 5270 (mU/ml). Todos presentaron hiperbilirrubinemia a predominio directa, aumento de la gamaglutamil transferasa y de Fosfatasa Alcalina. Se demostró circulación en Uruguay del VHE con manifestaciones clínicas, lo que traduce la presencia de una enfermedad emergente. Se plantea introducir el diagnostico del VHE en forma protocolizada en pacientes sin diagnostico etiológico de hepatitis

Human immunodeficiency virus/hepatits C virus coinfection in Spain: Elimination is feasible, but the burden of residual cirrhosis will be significant

Background We assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies performed in 2002, 2009, and 2015. Methods The study was performed in 43 centers during October-November 2016. The sample was estimated for an accuracy of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-acting antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV transmissibility. Results The reference population and the sample size were 38904 and 1588 patients, respectively. The prevalence of HCV-Abs in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (P trend <.001, from 2002 to 2015). The prevalence of active HCV in 2002, 2009, 2015, and 2016 was 54.0%, 34.0%, 22.1%, and 11.7%, respectively (P trend <.001). The anti-HCV treatment uptake in 2002, 2009, 2015, and 2016 was 23.0%, 48.0%, 59.3%, and 74.7%, respectively (P trend <.001). In 2016, HCV-related cirrhosis was present in 7.6% of all HIV-infected individuals, 15.0% of patients with active HCV, and 31.5% of patients who cleared HCV after anti-HCV therapy. Conclusions Our findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the burden of HCV-related cirrhosis will continue to be significant among HIV-infected individuals

Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019

Altres ajuts: Spanish AIDS Research Network; European Funding for Regional Development (FEDER).Objectives: We assessed the prevalence of anti-hepatitis C virus (HCV) antibodies and active HCV infection (HCV-RNA-positive) in people living with HIV (PLWH) in Spain in 2019 and compared the results with those of four similar studies performed during 2015-2018. Methods: The study was performed in 41 centres. Sample size was estimated for an accuracy of 1%. Patients were selected by random sampling with proportional allocation. Results: The reference population comprised 41 973 PLWH, and the sample size was 1325. HCV serostatus was known in 1316 PLWH (99.3%), of whom 376 (28.6%) were HCV antibody (Ab)-positive (78.7% were prior injection drug users); 29 were HCV-RNA-positive (2.2%). Of the 29 HCV-RNA-positive PLWH, infection was chronic in 24, it was acute/recent in one, and it was of unknown duration in four. Cirrhosis was present in 71 (5.4%) PLWH overall, three (10.3%) HCV-RNA-positive patients and 68 (23.4%) of those who cleared HCV after anti-HCV therapy (p = 0.04). The prevalence of anti-HCV antibodies decreased steadily from 37.7% in 2015 to 28.6% in 2019 (p < 0.001); the prevalence of active HCV infection decreased from 22.1% in 2015 to 2.2% in 2019 (p < 0.001). Uptake of anti-HCV treatment increased from 53.9% in 2015 to 95.0% in 2019 (p < 0.001). Conclusions: In Spain, the prevalence of active HCV infection among PLWH at the end of 2019 was 2.2%, i.e. 90.0% lower than in 2015. Increased exposure to DAAs was probably the main reason for this sharp reduction. Despite the high coverage of treatment with direct-acting antiviral agents, HCV-related cirrhosis remains significant in this population

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

Use of emergency medical transport and impact on time to care in patients with ischaemic stroke

Introduction: According to numerous studies, using emergency medical services (EMS) to transport stroke patients to hospitals decreases diagnostic and treatment delays. Objectives: To determine the frequency of use of EMS by stroke patients in Bizkaia (Spain), analyse the factors associated with using EMS, and study the impact of EMS on time to care. Methods: We gathered data from 545 patients hospitalised for acute ischaemic stroke and recruited consecutively. Data were obtained from the patients’ medical histories and interviews with the patients themselves or their companions. We studied the following variables: previous health status, stroke symptoms and severity (NIHSS), type of transport, and time to medical care. Univariate and multivariate analyses were performed to identify factors associated with use of EMS and care delays. Results: Patients transported to hospital by the EMS accounted for 47.2% of the total. Greater stroke severity, arriving at the hospital at night, and poor functional status at baseline were found to be independently associated with use of EMS. Use of EMS was linked to earlier arrival at the hospital. Door-to-imaging times were shorter in the EMS group; however, this association disappeared after adjusting for stroke severity. Revascularisation was more frequent among patients transported by the EMS. Conclusions: EMS transport was associated with shorter prehospital delays. Effective health education programmes should be developed to promote EMS transport for patients with stroke symptoms. In-hospital stroke management should also be improved to reduce time to medical care. Resumen: Introducción: Numerosos estudios han establecido que el traslado al hospital de los pacientes con ictus por los servicios de transporte sanitario urgente (TSU) implica demoras menores hasta el diagnóstico y tratamiento. Objetivos: Determinar la frecuencia de uso de TSU por los pacientes con ictus en Bizkaia (España), qué factores se asocian con el mismo y el impacto del medio de transporte en los tiempos de atención. Métodos: Se analizaron los datos de 545 pacientes con ictus isquémico agudo hospitalizados y reclutados consecutivamente. Se obtuvieron datos por entrevista a pacientes o acompañantes y de historia clínica. Se estudiaron variables sobre situación previa, síntomas y gravedad (NIHSS) del ictus, modalidad de traslado y tiempos de atención. Se realizaron análisis univariados y multivariados para identificar factores asociados al uso de TSU y con las demoras. Resultados: El 47,2% de los pacientes llegaron al hospital trasladados por TSU. Una mayor gravedad del ictus, la llegada al hospital en horario nocturno y un peor estado funcional previo resultaron asociados de forma independiente con el TSU. El TSU se asoció a una llegada más precoz al hospital. La demora puerta-imagen fue menor en el grupo TSU, pero la asociación desapareció al ajustar por gravedad. La revascularización fue más frecuente entre los trasladados por TSU. Conclusiones: El TSU se asoció a menor demora prehospitalaria. Es necesario desarrollar programas efectivos de educación sanitaria para incrementar el uso de TSU ante los síntomas del ictus. Debe mejorarse la gestión intrahospitalaria del ictus para reducir los tiempos de atención. Keywords: Stroke, Emergency medical services, Stroke symptoms, Stroke management, In-hospital delay, Code stroke, Palabras clave: Ictus, Servicios de emergencias médicas, Síntomas de ictus, Atención al ictus, Demora intrahospitalaria, Código ictu

Utilización de transporte sanitario urgente por los pacientes con ictus isquémico e impacto en los tiempos de atención

Resumen: Introducción: Numerosos estudios han establecido que el traslado al hospital de los pacientes con ictus por los servicios de transporte sanitario urgente (TSU) implica demoras menores hasta el diagnóstico y tratamiento. Objetivos: Determinar la frecuencia de uso de TSU por los pacientes con ictus en Bizkaia (España), qué factores se asocian con el mismo y el impacto del medio de transporte en los tiempos de atención. Métodos: Se analizaron los datos de 545 pacientes con ictus isquémico agudo hospitalizados y reclutados consecutivamente. Se obtuvieron datos por entrevista a pacientes o acompañantes y de historia clínica. Se estudiaron variables sobre situación previa, síntomas y gravedad (NIHSS) del ictus, modalidad de traslado y tiempos de atención. Se realizaron análisis univariados y multivariados para identificar factores asociados al uso de TSU y con las demoras. Resultados: El 47,2% de los pacientes llegaron al hospital trasladados por TSU. Una mayor gravedad del ictus, la llegada al hospital en horario nocturno y un peor estado funcional previo resultaron asociados de forma independiente con el TSU. El TSU se asoció a una llegada más precoz al hospital. La demora puerta-imagen fue menor en el grupo TSU, pero la asociación desapareció al ajustar por gravedad. La revascularización fue más frecuente entre los trasladados por TSU. Conclusiones: El TSU se asoció a menor demora prehospitalaria. Es necesario desarrollar programas efectivos de educación sanitaria para incrementar el uso de TSU ante los síntomas del ictus. Debe mejorarse la gestión intrahospitalaria del ictus para reducir los tiempos de atención. Abstract: Introduction: According to numerous studies, using emergency medical services (EMS) to transport stroke patients to hospitals decreases diagnostic and treatment delays. Objectives: To determine the frequency of use of EMS by stroke patients in Bizkaia (Spain), analyse the factors associated with using EMS, and study the impact of EMS on time to care. Methods: We gathered data from 545 patients hospitalised for acute ischaemic stroke and recruited consecutively. Data were obtained from the patients’ medical histories and interviews with the patients themselves or their companions. We studied the following variables: previous health status, stroke symptoms and severity (NIHSS), type of transport, and time to medical care. Univariate and multivariate analyses were performed to identify factors associated with use of EMS and care delays. Results: Patients transported to hospital by the EMS accounted for 47.2% of the total. Greater stroke severity, arriving at the hospital at night, and poor functional status at baseline were found to be independently associated with use of EMS. Use of EMS was linked to earlier arrival at the hospital. Door-to-imaging times were shorter in the EMS group; however, this association disappeared after adjusting for stroke severity. Revascularisation was more frequent among patients transported by the EMS. Conclusions: EMS transport was associated with shorter prehospital delays. Effective health education programmes should be developed to promote EMS transport for patients with stroke symptoms. In-hospital stroke management should also be improved to reduce time to medical care. Palabras clave: Ictus, Servicios de emergencias médicas, Síntomas de ictus, Atención al ictus, Demora intrahospitalaria, Código ictus, Keywords: Stroke, Emergency medical services, Stroke symptoms, Stroke management, In-hospital delay, Code strok